Skip Nav Destination
Issues
1 January 2011
-
Cover Image
Cover Image
Human glioma tumor initiating cells are targets for telomerase inhibition. Immunofluorescence studies show that glioma tumor-initiating cells express high levels of nestin (neuronal precursor cells marker, shown in green). These cells have substantially higher telomerase activity then normal tissue stem cells and can therefore be specifically and safely targeted for telomerase inhibition. For further details, please see Castelo-Branco and coworkers on page 111 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR New Strategies
Molecular Pathways
Review
Human Cancer Biology
Frequent hSNF5/INI1 Germline Mutations in Patients with Rhabdoid Tumor
Franck Bourdeaut; Delphine Lequin; Laurence Brugières; Stéphanie Reynaud; Christelle Dufour; François Doz; Nicolas André; Jean-Louis Stephan; Yves Pérel; Odile Oberlin; Daniel Orbach; Christophe Bergeron; Xavier Rialland; Paul Fréneaux; Dominique Ranchere; Dominique Figarella-Branger; Georges Audry; Stéphanie Puget; D. Gareth Evans; Joan Carles Ferreres Pinas; Valeria Capra; Véronique Mosseri; Isabelle Coupier; Marion Gauthier-Villars; Gaëlle Pierron; Olivier Delattre
Long Exposure of Environmental Tobacco Smoke Associated with Activating EGFR Mutations in Never-Smokers with Non–Small Cell Lung Cancer
Tomoya Kawaguchi; Masahiko Ando; Akihito Kubo; Minoru Takada; Shinji Atagi; Kyoichi Okishio; Kazuhiro Asami; Akihide Matsumura; Kazuyuki Tsujino; Ou Sai-Hong Ignatius; Hidefumi Sasaki
Ewing Tumors That Do Not Overexpress BMI-1 Are a Distinct Molecular Subclass with Variant Biology: A Report from the Children's Oncology Group
Aaron Cooper; John van Doorninck; Lingyun Ji; Darren Russell; Marc Ladanyi; Hiroyuki Shimada; Mark Krailo; Richard B. Womer; Jessie Hao-ru Hsu; Dafydd Thomas; Timothy J. Triche; Richard Sposto; Elizabeth R. Lawlor
Cancer Therapy: Preclinical
Interleukin-6 Modulates Graft-versus-Host Responses after Experimental Allogeneic Bone Marrow Transplantation
Isao Tawara; Motoko Koyama; Chen Liu; Tomomi Toubai; Dafydd Thomas; Rebecca Evers; Peter Chockley; Evelyn Nieves; Yaping Sun; Kathleen P. Lowler; Chelsea Malter; Norihiro Nishimoto; Geoffrey R. Hill; Pavan Reddy
Neural Tumor-Initiating Cells Have Distinct Telomere Maintenance and Can be Safely Targeted for Telomerase Inhibition
Pedro Castelo-Branco; Cindy Zhang; Tatiana Lipman; Mayumi Fujitani; Loen Hansford; Ian Clarke; Calvin B. Harley; Robert Tressler; David Malkin; Erin Walker; David R. Kaplan; Peter Dirks; Uri Tabori
Antitumor Activity of SNX-2112, a Synthetic Heat Shock Protein-90 Inhibitor, in MET-Amplified Tumor Cells with or without Resistance to Selective MET Inhibition
Thomas Bachleitner-Hofmann; Mark Y. Sun; Chin-Tung Chen; David Liska; Zhaoshi Zeng; Agnes Viale; Adam B. Olshen; Martina Mittlboeck; James G. Christensen; Neal Rosen; David B. Solit; Martin R. Weiser
The Ability to Form Primary Tumor Xenografts Is Predictive of Increased Risk of Disease Recurrence in Early-Stage Non–Small Cell Lung Cancer
Thomas John; Derek Kohler; Melania Pintilie; Naoki Yanagawa; Nhu-An Pham; Ming Li; Devang Panchal; Frances Hui; Fannong Meng; Frances A. Shepherd; Ming-Sound Tsao
Imaging, Diagnosis, Prognosis
Prognostic Significance of the Detection of Peripheral Blood CEACAM5mRNA-Positive Cells by Real-Time Polymerase Chain Reaction in Operable Colorectal Cancer
Nikolaos Vardakis; Ippokratis Messaritakis; Chara Papadaki; Georgios Agoglossakis; Maria Sfakianaki; Zacharenia Saridaki; Stella Apostolaki; Ioannis Koutroubakis; Maria Perraki; Dora Hatzidaki; Dimitris Mavroudis; Vassilis Georgoulias; John Souglakos
Cancer Therapy: Clinical
Total Marrow Irradiation: A New Ablative Regimen as Part of Tandem Autologous Stem Cell Transplantation for Patients with Multiple Myeloma
George Somlo; Ricardo Spielberger; Paul Frankel; Chatchada Karanes; Amrita Krishnan; Pablo Parker; Leslie Popplewell; Firoozeh Sahebi; Neil Kogut; David Snyder; An Liu; Timothy Schultheiss; Stephen Forman; Jeffrey Y. C. Wong
Phase I Study of E7820, an Oral Inhibitor of Integrin α-2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies
Monica Mita; Kevin R. Kelly; Alain Mita; Alejandro D. Ricart; Ofelia Romero; Anthony Tolcher; Laurel Hook; Chukwuemeka Okereke; Ilya Krivelevich; Daniel P. Rossignol; Francis J. Giles; Eric K. Rowinsky; Chris Takimoto
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds